Abstract
Rômulo Piloni-Parreira, Melaine Stefane Barbosa, Laís Lauria Neves, Hernani Lopes Santana, João Marcos Ranyere da Silva Rodrigues, Renato Sampaio Tavares, David Leonardo Cruvinel Isaac, Marcos Pereira de Ávila
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Molecular profiling in MPN: who should have it and why?
10.1182/hematology.2024000576 · 2024
Ocular manifestations in patients with philadelphia-negative myeloproliferative neoplasms
10.3390/cancers12030573 · 2020
Ocular manifestations in hematological disorders
2022
Augenveränderungen bei hämatologischen Erkrankungen [Ocular findings in hematological diseases]
10.1007/s00347-011-2430-x · 2011
Ophthalmic manifestations in patients with blood malignancies
10.3390/hematolrep16020020 · 2024
Ocular involvement in leukemia–a study of 288 cases
10.1159/000073077 · 2003
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden
10.1182/blood-2008-03-143602 · 2008
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
10.1182/blood-2015-06-652941 · 2016
Characterization of myeloproliferative neoplasms in the pediatric and young adult population
10.1111/bjh.18650 · 2023
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
10.1111/bjh.14061 · 2016
MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis
10.1200/jco.2018.78.9867 · 2018
Adolescent and young adult oncology: an emerging field
10.1200/jco.2010.30.5128 · 2010
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT
10.1016/s2352-3026(22)00330-1 · 2023
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
10.1182/blood.2023020232 · 2024
The 5th edition of the world health organization classification of haematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022
Epidemiology of MPN: what do we know?
10.1007/s11899-014-0228-z · 2014
Advances in molecular understanding of polycythemia vera, essential thrombocythemia, and primary myelofibrosis: towards precision medicine
10.3390/cancers16091679 · 2024
Advances in myelodysplastic/myeloproliferative neoplasms
10.1007/s00428-022-03465-7 · 2023
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
10.1186/s13045-017-0425-z · 2017
Myeloproliferative neoplasms: contemporary review and molecular landscape
10.3390/ijms242417383 · 2023
Somatic mutations of calreticulin in myeloproliferative neoplasms
10.1056/nejmoa1311347 · 2013
Age-related macular degeneration in patients with chronic myeloproliferative neoplasms
10.1001/jamaophthalmol.2017.2011 · 2017
The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms
10.1093/eurheartj/ehab447 · 2021
Diagnosis and treatment of polycythemia vera: a review
10.1001/jama.2024.20377 · 2025
Myeloproliferative neoplasms and cardiovascular disease: a review
10.1007/s11864-024-01255-8 · 2024
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates
10.1016/j.jaapos.2012.04.006 · 2012
Bleeding complications in JAK2-variant essential thrombocythemia: a revisit in 2025
10.1002/jha2.70088 · 2025
Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography
10.1111/bjh.12290 · 2013
Intermittent retinal artery occlusions as the first clinical manifestation of polycythemia vera: a case report
10.1186/s12886-022-02423-w · 2022
High levels of C5a are associated with reduced macular sensitivity in patients with myeloproliferative neoplasms
10.1167/iovs.66.2.41 · 2025
High levels of C5a are associated with reduced macular sensitivity in patients with myeloproliferative neoplasms
10.1167/iovs.66.2.41 · doi-reference
Intermittent retinal artery occlusions as the first clinical manifestation of polycythemia vera: a case report
10.1186/s12886-022-02423-w · doi-reference
Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography
10.1111/bjh.12290 · doi-reference
Bleeding complications in JAK2-variant essential thrombocythemia: a revisit in 2025
10.1002/jha2.70088 · doi-reference
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates
10.1016/j.jaapos.2012.04.006 · doi-reference
Myeloproliferative neoplasms and cardiovascular disease: a review
10.1007/s11864-024-01255-8 · doi-reference
Diagnosis and treatment of polycythemia vera: a review
10.1001/jama.2024.20377 · doi-reference
The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms
10.1093/eurheartj/ehab447 · doi-reference
Age-related macular degeneration in patients with chronic myeloproliferative neoplasms
10.1001/jamaophthalmol.2017.2011 · doi-reference
Somatic mutations of calreticulin in myeloproliferative neoplasms
10.1056/nejmoa1311347 · doi-reference
Myeloproliferative neoplasms: contemporary review and molecular landscape
10.3390/ijms242417383 · doi-reference
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
10.1186/s13045-017-0425-z · doi-reference
Advances in myelodysplastic/myeloproliferative neoplasms
10.1007/s00428-022-03465-7 · doi-reference
Advances in molecular understanding of polycythemia vera, essential thrombocythemia, and primary myelofibrosis: towards precision medicine
10.3390/cancers16091679 · doi-reference
Epidemiology of MPN: what do we know?
10.1007/s11899-014-0228-z · doi-reference
The 5th edition of the world health organization classification of haematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · doi-reference
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
10.1182/blood.2023020232 · doi-reference
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT
10.1016/s2352-3026(22)00330-1 · doi-reference
Adolescent and young adult oncology: an emerging field
10.1200/jco.2010.30.5128 · doi-reference
MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis
10.1200/jco.2018.78.9867 · doi-reference
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
10.1111/bjh.14061 · doi-reference
Characterization of myeloproliferative neoplasms in the pediatric and young adult population
10.1111/bjh.18650 · doi-reference
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
10.1182/blood-2015-06-652941 · doi-reference
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden
10.1182/blood-2008-03-143602 · doi-reference
Ocular involvement in leukemia–a study of 288 cases
10.1159/000073077 · doi-reference
Ophthalmic manifestations in patients with blood malignancies
10.3390/hematolrep16020020 · doi-reference
Augenveränderungen bei hämatologischen Erkrankungen [Ocular findings in hematological diseases]
10.1007/s00347-011-2430-x · doi-reference
Ocular manifestations in patients with philadelphia-negative myeloproliferative neoplasms
10.3390/cancers12030573 · doi-reference
Molecular profiling in MPN: who should have it and why?
10.1182/hematology.2024000576 · doi-reference